| OUTLOOK THERAPEUTICS |
| USA |
| Gesundheit |
| US69012T3059 / A4046T |
| 41O (Frankfurt) / OTLK (NASDAQ) |
| FRA:41O, ETR:41O, 41O:GR, NASDAQ:OTLK |
| - |
| https://outlooktherapeuti.. |
|
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal in..
>Volltext.. |
| 102.11 Mio. EUR |
| 108.41 Mio. EUR |
| - |
| - |
| - |
| - |
| 16.51 Mio. EUR |
| 10.07 Mio. EUR |
| - |
| 0.39 |
| - |
| - |
| - |
| - |
| - |
| - |
| OUTLOOK THERAPEUTICS, OUTLOOK THERAPEUTIC |
| 31.10.26 |